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Abstract
Background: Benznidazole (Bz)-chemotherapy is recommended to prevent Chagas disease progression, despite its
limited efficacy during chronic disease. However, the host mechanisms underlying these benefits still remain to be
elucidated.
Methods: In this study, we have used short-term whole blood cultures to describe the cytokine profile of Bz-
treated Indeterminate Chagas disease patients-(INDt) as compared to untreated patients-(IND).
Results: Our findings showed that IND presented increased levels of IL-10+neutrophils, IL-12+ and IL-10+monocytes
and IFN-γ+NK-cells. Moreover, IND showed slight increase of IL-4+CD4+T-cells and enhanced levels of IL-10+CD8+T-cells
and B-cells. Additional analysis of cytokine Low and High producers also highlighted the presence of High cytokine
producers within IND, including IL-10 from CD4+ T-cells and IFN-γ from CD8+ T-cells, as compared to NI. The Bz-
treatment lead to an overall cytokine down-regulation in the innate and adaptive compartments, including low levels of
IL-12+ and IL-10+neutrophils and monocytes, IFN-γ+NK-cells, IL-12+, TNF-α+, IFN-γ+ and IL-5+CD4+T-cells and IL-10+B-cells,
along with basal levels of cytokine-expressing CD8+T-cells in INDt as compared to IND. The in vitro antigen stimulation
shifted the cytokine profile toward a type 1-modulated profile, with increased levels of IL-12+ and IL-10+
monocytes, IFN-γ+ and IL-4+NK-cells along with TNF-α+ and IFN-γ+CD8+T-cells. Analysis of Low and High cytokine
producers, upon in vitro antigen stimulation, further confirm these data.
Conclusion: Together, our findings showed that the Bz treatment of Indeterminate Chagas’ disease patients shifts the
cytokine patterns of peripheral blood monocytes, NK-cells and CD8+ T-cells towards a long-lasting Type-1-modulated
profile that could be important to the maintenance of a non-deleterious immunological microenvironment.
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Background
An outstanding triumph of the Brazilian medicine was
the discovery of Chagas disease by Carlos Chagas at the
beginning of the 20th century. One century after the dis-
covery, several aspects of Chagas disease still remain un-
clear, including those regarding to the multiple events of
pathogenesis underlying the clinical progression, as well
as the mechanisms implicated in the successful etio-
logical treatment.
Chagas disease is caused by the haemoflagellate proto-
zoan Trypanosoma cruzi and is considered one of the
most important public health problems in Latin
America, affecting approximately 8 to 10 million people
and a further 100 million people are considered at risk
of infection [1].
The major mechanism associated with Chagas disease
pathology is the continuous inflammatory infiltrate
observed mainly in the cardiac and digestive tract organs
characterized by damages in the neuronal conductive
systems and also by muscle cytolysis [2]. There is a
growing consensus that complex co-adaptation between
the persistent parasite infection and the balanced host
immune response underlies the establishment of
Indeterminate clinical form of Chagas disease. On the
hand the persistence of parasite along with unbalanced
immune response leads to a sustained inflammatory re-
sponse that supports these characteristic lesions of
chronic Chagas disease [2]. In this immunopathogenesis
paradigm the eradication of T. cruzi may be a pre-
requisite to control the disease progression and prevent
the irreversible long-term consequence of Chagas dis-
ease. Therefore, Chagas disease must be treated primar-
ily as an infectious disease, and not as autoimmune
disorder, in contrast to long-held views [3].
Specific chemotherapy is recommended for the treat-
ment of Chagas disease applying the general assumption
that the earlier the specific treatment is initiated greater
are the chances of parasitological cure and clinical bene-
fits to the host [4]. At present, Chagas disease chemo-
therapy is restricted to two drugs, Benznidazole (Bz) and
nifurtimox (Nfx). In Brazil, only Bz has been used to
etiological treatment of Chagas disease [5] with higher
cure ratio observed during acute, congenital and early
chronic Indeterminate Chagas disease [4-6]. Despite the
low cure rates observed in most patients submitted to
treatment during chronic Chagas disease, several studies
have suggested that the Bz-treatment should be still
recommended during chronic Chagas disease, since it
prevents the disease progression, regardless of lack of
complete parasite clearance [7-9]. The mechanism of ac-
tion of benznidazole is not completely clear. It has been
proposed that the BZ-mediated trypanocidal mechanism
is effective because the nitro group is reduced by para-
site enzymes to produce free radicals, superoxide anions,
and hydrogen peroxide [10]. One of the major factors
potentially influencing the parasite clearance as well as
the morbidity control following the treatment for
Chagas’ disease is the cooperative action between the
drug effects and the host immunological response [11-14].
However little is known about the changes in the host im-
mune following Bz treatment, specifically during chronic
Indeterminate Chagas disease that could synergistically act
with the BZ-therapy. The coherent understanding of these
changes will certainly support the development of new
protocol for Bz therapy, intervention and management of
chronic Chagas disease. We believe that the analysis of host
immunity status pre- and post-treatment is essential to fur-
ther elucidate the impact of Bz intervention as well as sup-
port the rational development of new trypanosomicidal
agents. We have previously shown that early after the end
of the Bz therapy, the NK-cells and CD8+ T-lymphocytes
are important sources of IFN-γ and that IL-10 produced by
CD4+ T-cells and B lymphocytes are putative key element
to modulate the immune response and control tissue dam-
age might inducible by the pro-inflammatory response. In
the current investigation we would like to test the hypoth-
esis that the Bz-therapy modulates the immune response
inducing a long-lasting impact on the immunological status
of treated patients, inducing a similar Type-1 modulated
cytokine profile as observed early after the end of the treat-
ment [13,14].
Our findings bring new insights to the hypothesis that
later on after the end of Bz-treatment, the patients pre-
sented a down-regulated cytokine pattern along with the
capacity to build a Type-1 modulated cytokine response,
upon T. cruzi antigen stimuli, supported by pro-
inflammatory cytokine from monocytes, NK and CD8+
T-cells, counterbalanced by IL-10 from monocytes.
Methods
Study population
This cross-sectional study involved 47 subjects classified
into three groups referred as IND – untreated Indetermin-
ate Chagas disease patients (n=15; 3 males and 12 females;
mean age=42.5± 5.5 years, ranging from 35–52 years);
INDt – Bz-treated Indeterminate Chagas disease patients
(n=14; 4 males and 10 females; mean age=44.0±8.7 years,
ranging from 33–56 years) and NI – non-infected
individuals (n=18, 7 males and 11 females, mean
age=29.0 ±9.7 years, ranging from 18–47 years).
Indeterminate Chagas disease was diagnosed by at
least two positive results on serological tests (indirect
hemagglutination, indirect immunofluorescence, or
enzyme-linked immunosorbent assay) and no alteration
in the clinical and physical examination, besides normal
electrocardiogram, chest X-ray, Holter, and echodoppler-
cardiography profiles. The IND patients were recruited
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at the Ambulatório de doença de Chagas, Hospital das
Clínicas, Universidade Federal de Minas Gerais (Belo
Horizonte, Minas Gerais, Brazil).
Benznidazole (N-benzyl-2-nitro-1-imidazolacetamide)
treatment was carried out in daily doses of 5 mg/kg of
body weight, twice a day for 60 days, according to the
Brazilian Ministry of Health [15]. The INDt patients
were recruited seven years after the end of etiological
treatment at the Ambulatório de doença de Chagas,
Hospital das Clínicas, Universidade Federal de Minas
Gerais (Belo Horizonte, Minas Gerais, Brazil).
The non-infected subjects showing negative serologic
tests for antibodies against T. cruzi were contacted at
the Centro de Hematologia e Hemoterapia de Minas
Gerais (Belo Horizonte, Minas Gerais, Brazil).
All study participants provided written informed con-
sent following the guidelines of Ethics Committee of the
Minas Gerais Federal University. The study protocol
complied with the regulations 196/1996 of Brazilian Na-
tional Council on Research in Humans and was also
approved by the Ethical Committee of Minas Gerais
Federal University under protocol # COEP-ETIC 070/00.
Blood samples
Five milliliters of whole peripheral blood were collected in
EDTA anticoagulant for hemogram analysis. Ten milliliters
of heparinized peripheral blood were collect from each par-
ticipant and used for short-term in vitro culture of whole
blood. Heparin whole blood samples were maintained at
room temperature for up to 12 hours prior processing.
Trypanosoma cruzi epimastigote antigen preparation
Soluble Epimastigote Antigen (EPI) was prepared from a
stationary phase Y strain T. cruzi epimastigotes grown in
LIT-medium. After the third or fourth in vitro passage,
epimastigotes were harvested, washed in 15 mM
phosphate-buffered saline (PBS), pH 7.4, and resus-
pended to 108 cells/mL in 15 mM PBS, pH 7.4. The sus-
pension was rapidly frozen at −70°C and thawed at 37°C
three times, with a sonication procedure between each
step. The crude lysate was centrifuged (37,000 g) for
90 min and the supernatant collected, dialysed overnight
against 15 mM PBS, pH 7.4, sterilized by filtration
through a 0.22-μm pore membrane (Filter millex, Mili-
pore Products Division, Billerica, MA, USA) and stored
at −70°C until use. The protein content was assayed by
the method described by Lowry et al. [16].
Short-term in vitro culture of whole blood
Short-term cultures in vitro were carried out as previ-
ously described by Sathler-Avelar et al., [14]. Briefly,
500μL aliquots of heparinized whole blood samples were
transferred into 14 mL polypropylene tubes (FalconW,
BD Pharmingen, San Jose, CA, USA) and incubated in
the presence of 500μL of RPMI-1640 (GIBCO, Grand Is-
land, NY, USA) – “Control Culture”; 500μL aliquots of
heparinized whole blood samples in the presence of EPI
soluble antigen at a final concentration of 20 μg/mL in
RPMI-1640 – “Stimulated Culture” or Phorbol 12-
Myristate 13-Acetate at 25 ng/mL plus ionomycin at
1 μg/mL (Sigma, St Louis, MO, USA) in RPMI-1640 –
“PMA stimulated culture”. The Control and Stimulated
cultures were pre-incubated for 1 h at 37°C, 5% CO2 in
a humidified incubator. Afterward, all cultures were
incubated for 4 h in at 37°C, 5% CO2 in a humidified in-
cubator in the presence of BFA at 10 μg/mL. Following
incubation, all cultures were treated with 100μL of
EDTA 2 mM in PBS for 15 min (Sigma, St Louis, MO,
USA) in order to block the activation process.
Immunophenotyping for cell subsets and intracellular
cytokines analysis
Following the short term in vitro stimulation, all cultures
were washed once with 3 mL of FACS buffer prepared
as PBS supplemented with 0.5% bovine serum albumin
and 0.1% sodium azide (Sigma, St Louis, MO, USA).
Samples were resuspended into 1 mL of FACS buffer.
Aliquots of 400μL were immunostained in the dark for
30 min at room temperature with 10μL of pre-diluted
TriColor-labelled monoclonal antibodies (mAbs) anti-
CD4, CD8, CD14, CD16 or CD19 (Caltag, Burlingame,
CA, USA). Following incubation, the erythrocyte lysing
and cell fixation procedures were performed by adding
2 mL of FACS lysing solution (BD, San Diego, CA, USA)
and incubation for 30 min at room temperature.
Membrane-stained leucocytes were permeabilized with
3 mL of FACS perm-buffer for 10 min at room
temperature (FACS buffer supplemented with 0.5% sap-
onin) and washed once with 2 mL of FACS buffer. Cell
suspension aliquots of 30μL were transferred to 96wells
round bottom microplates (FalconW; BD Pharmingen,
San Jose, CA, USA) were stained for 30 min at room
temperature, in the dark in the presence of 20μL of PE-
labelled anti-cytokine mAbs (IL-12, TNF-α, IFN-γ, IL-4,
IL-5 and IL-10). All antibodies were diluted 1:50 in
FACS perm-buffer and were purchased from BD Phar-
mingen (San Diego, CA, USA). After intracytoplasmic
cytokine staining, the cells were washed twice with
200μL of FACS perm-buffer and FACS buffer, respect-
ively, and then fixed in 200μL of FACS FIX Solution
(10 g/L of paraformaldehyde, 10.2 g/L of sodium cacodi-
late and 6.63 g/L of sodium chloride, pH 7.2, all from
Sigma, St Louis, MO, USA). The samples were stored at
4°C prior flow cytometry acquisition and analysis.
Flow cytometry acquisition and analysis
Flow cytometry acquisition of 30,000 immunestained
cells/samples were performed in a FACScaliburW flow
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cytometer equipped with CELLQUESTTM software
(Becton Dickinson, San Jose, CA, USA). Distinct gating
strategies were used to analyze the cytokine-expressing
leucocyte subpopulations from the innate (monocytes,
neutrophils and NK-cells) and adaptive immunity
(lymphocytes as well as T- and B-cell subsets). The
monocytes were selected as CD14High+ cells and the
neutrophil as SSCHighCD14Low+ cells on FL3/anti-CD14-
TC versus SSC/laser side-scatter dot plots. The
lymphocyte populations were selected on FSC/laser
forward-scatter versus SSC/laser side-scatter dot plots.
Following the initial gate selection, the frequencies of
cytokine+ cells were quantified by quadrant statistics
applied on FSC/laser forward-scatter versus FL2/anti-
cytokine-PE dot plots for monocytes and neutrophils
and FL3/anti-CD16, CD4, CD8 or CD19 TC versus FL2/
anti-cytokine-PE dot plots for NK-cells, T-lymphocyte
subsets and B-cells.
Analysis of low and high cytokine-producers
The analysis of cytokine-producers within IND and
INDt groups were performed by first taking the median
value of cytokine+ cells from each leucocyte subpopula-
tion (neutrophils, monocytes, NK-cells, CD4+ and CD8+
T-cells and B-cells) from the NI group as the cut-off
edge to categorize the subjects as Low and High
cytokine-producers. Gray-scale diagrams were used to
assemble the prevalence of Low (empty rectangle), High in-
flammatory (black rectangle for IL-12, TNF-α and IFN-γ)
or High regulatory (gray rectangle for IL-4, IL-5 and IL-10)
cytokine-producers amongst IND and INDt groups. Bar
charts were applied to compile the frequency of Low and
High cytokine-producers within each leucocyte subset.
Statistical analysis
Statistical analysis was performed using the GraphPad
Prism 5 software package (San Diego, CA, USA). As all
data files assume a non-Gaussian distribution, statistical
comparisons were carried out using the nonparametric
Kruskal-Wallis test followed by Dunns multiple comparison
test to evaluate the cytokine profiles among NI, IND and
INDt groups. The comparative analyses between control
culture and stimulated culture were performed by
Wilcoxon matched pairs test. The frequency of high and
low cytokine-producers was compared by contingency table
analysis by Chi-square test. The differences were consid-
ered significant when p-values were <0.05.
Results
Cytokine profile of innate immunity in indeterminate
chagas disease patients
The number of inflammatory and regulatory cytokines,
expressed by the innate immunity cells, from Indeter-
minate Chagas disease patients is shown in Figure 1.
Data from the control culture showed a prominent
anti-inflammatory cytokine pattern in neutrophils from
IND as compared to NI, represented by enhanced levels
of IL-10+ cells and basal levels of IL-12+ cells
(Figure 1A, left panel). Upon in vitro antigen stimula-
tion, a similar anti-inflammatory cytokine profile was
observed in IND, with increased number of IL-10+ neu-
trophils as compared to the NI and control culture
(Figure 1A, right panel).
The analyses of monocytes reveled a mixed inflamma-
tory/anti-inflammatory cytokine pattern in IND as com-
pared to NI, with increased levels of IL-12+ and IL-10+
cells (Figure 1B, left panel). This mixed profile was pre-
served after in vitro antigen stimulation, as shown by the
increased number of IL-12+ and IL-10+ monocytes in
IND as compared to NI (Figure 1B, right panel).
Analysis of NK-cells showed a predominant inflammatory
cytokine pattern in IND, with higher number of IFN-γ+
cells and basal levels of IL-4+ cells as compared to NI
(Figure 1C, left panel). Upon in vitro antigen stimulation,
despite no difference in the number of IFN-γ+ cells, the
lower levels of IL-4+ cells count to the predominant inflam-
matory cytokine pattern of NK-cells observed in IND as
compared to NI (Figure 1C, right panel).
Impact of bz-treatment on the cytokine pattern of innate
immunity of indeterminate chagas disease patients
In order to investigate the impact of etiological treat-
ment on the cytokine profile of innate immunity of
Indeterminate Chagas disease patients, we have com-
pared the cytokine profile of neutrophils, monocytes and
NK-cells from INDt as compared to IND. These differ-
ences are highlighted by connecting lines.
Data analyses showed an overall cytokine down-
regulation in the innate immunity compartment after
benznidazole therapy, as shown by the lower levels of
IL-12+, IL-10+ neutrophils and monocytes, as well as
reduced levels of IFN-γ+ NK-cells in INDt as compared
to IND (Figure 1A, B and C, left panel).
However, the in vitro antigen stimulation was able to
shift the cytokine expression by monocytes and NK-cells
toward a type 1-regulated immune profile, with
increased levels of IL-12 and IFN-γ respectively counter-
balanced by IL-10 from monocytes (Figure 1B and C,
right panel), despite no changes in the cytokine profile
of neutrophils (Figure 1A, right panel).
Cytokine profile of adaptive immunity in indeterminate
chagas disease patients
The levels of inflammatory and regulatory cytokine-
expressing cells in the adaptive immunity compartment
from Indeterminate Chagas disease patients are shown
in Figures 2, 3 and 4.
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Data from the control culture showed a small shift
towards a anti-inflammatory cytokine pattern in CD4+
T-lymphocytes from IND as compared to NI, repre-
sented by a slight increase in the number of IL-4+ along
with the basal numbers of TNF-α+, IL-12+, IFN-γ+, IL-5+
and IL-10+ cells (Figure 2A). Upon in vitro antigen stimula-
tion despite the general basal levels of cytokines observed
for CD4+ T-cells, the small decrease in the IL-12+ cells
could support the small shift towards a anti-inflammatory
cytokine pattern in CD4+ T-lymphocytes.
A typical anti-inflammatory cytokine profile was observed
for both CD8+ T-lymphocytes and B-cells from IND as
compared to NI, represented by increased levels of IL-10+


















































































































































Figure 1 Analysis of intracytoplasmic cytokine profile of neutrophils. (A), monocytes (B) and NK-cells in the peripheral blood from non
treated Indeterminate chagasic patients (IND gray rectangle), Bz-treated Indeterminate chagasic patients (INDt black rectangle) as compared to
non-infected individual (NI empty rectangle). Data are expressed as median absolute counts plus the interquartile range of cytokine+ cells
observed after short-term in vitro “Control Culture” (left panels) and T. cruzi epimastigote antigen “Stimulated Culture” (right panels) of whole-
blood samples. Cytokine+ neutrophils, monocytes and NK-cells were quantified by dual color immunophenotyping (anti-CD14-TC or anti-CD16-TC
plus anti-cytokine-PE mAbs) using specific gate strategies to select each leucocyte subset, as described in Material and Methods. The significant
differences at p<0.05 for comparisons with NI are indicated by the letter ‘a’. The significant differences at p<0.05 for comparisons with INDt are
indicated by connecting lines. The significant differences at p<0.05 for comparative analysis between “Control” and “Stimulated” cultures are
indicated by *.
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(Figure 3A and 4A). Upon in vitro antigen stimulation, des-
pite the increased number of IFN-γ+CD8+ T-lymphocytes
and TNF-α+ B-cells observed in comparison to the control
culture, a anti-inflammatory cytokine profile still remain
preponderant in both CD8+ T-lymphocytes and B-cells
from IND as compared to NI (Figures 3B and 4B).
Impact of bz-treatment on the cytokine pattern of
adaptive immunity of indeterminate chagas disease
patients
The comparative analysis of cytokine-expressing cells in
the adaptive immunity compartment after the etiological
treatment is shown in Figures 2, 3 and 4.
Data from the control culture showed an overall cyto-
kine down-regulation in CD4+ T-cells from INDt as
compared with IND and NI, with decreased levels of
IL-12+, TNF-α+, IFN-γ+ and IL-5+ cells, along with basal
numbers of IL-4+ and IL-10+ cells (Figure 2A) with no
changes observed after the in vitro antigen stimulation
(Figure 2B).
On the other hand, despite the basal levels of
cytokine-expressing CD8+ T-cells observed in the con-
trol cultures from INDt as compared to IND
(Figure 3A), the in vitro antigen stimulation was able to
drive the CD8+ T-cells towards a inflammatory cytokine
profile, with increased numbers of TNF-α+ and IFN-γ+
CD8+ T-cells in INDt as compared to IND and NI
(Figure 3B).
Data analysis from the control cultures also showed a
cytokine down-regulation in B-cells from INDt as com-
pared with IND and NI, with decreased levels of IL-10+
cells (Figure 4A) which remain after in vitro antigen
stimulation, regardless of slight increase in TNF-α+
B-cells observed in comparison to the control cul-
ture (Figure 4B).
Analysis of low and high cytokine-producers amongst
indeterminate chagas disease patients
As previously report by Bahia-Oliveira et al. [17] and





























































Figure 2 Analysis of intracytoplasmic cytokine profile of CD4+. T-lymphocytes in the peripheral blood from untreated Indeterminate
chagasic patients (IND gray rectangle), Bz-treated Indeterminate chagasic patients (INDt black rectangle) as compared to non-infected individual
(NI empty rectangle). Data are expressed as median absolute counts plus the interquartile range of cytokine+ cells observed after short-term
in vitro “Control Culture” (top panel) and T. cruzi epimastigote antigen “Stimulated Culture” (bottom panel) of whole-blood samples. Cytokine+
CD4+ T-cells were quantified by dual color immunophenotyping (anti-CD4-TC plus anti-cytokine-PE mAbs) using specific gate strategy, as
described in Material and Methods. The significant differences at p< 0.05 for comparisons with NI are indicated by the letter ‘a’. The significant
differences at p< 0.05 for comparisons with INDt are indicated by connecting lines. The significant differences at p< 0.05 for comparative
analysis between “Control” and “Stimulated” cultures are indicated by *.
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cytokine-producers represents a powerful tool to charac-
terize distinct immunological profiles in Chagas disease
patients (Figure 5A and B, top panels). The frequencies of
High cytokine-producers in the IND and INDt groups were
obtained considering the median of a given cytokine+ cells
from the NI group as the cut-off edge to categorize the sub-
jects as Low and High cytokine-producers. We have used
gray-scale diagrams to assemble the frequency of Low
(empty rectangle), High inflammatory (black rectangle) and
regulatory (gray rectangle) cytokine-producers amongst
IND and INDt groups. Using this concept, our data con-
firmed the presence of a type-1 modulated cytokine profile
within innate immunity cells, with enhanced frequency of
High cytokine producers, including IL-10 from neu-
trophils, IL-12 and IL-10 from monocytes and IFN-γ
from NK-cells. The analysis of the adaptive compart-
ment also confirmed the presence of a predominant
anti-inflammatory immune response in CD4+, CD8+
and B-cells and additionally pointed out the presence
of High cytokine producers including IL-10 from CD4+
T-cells and IFN-γ from CD8+ T-cells (Figure 5A top panel).
No differences were observed in the frequency of Low
and High producers between control and stimulated cul-
tures from IND (Figure 4A and B, top panel).
Impact of bz-treatment of the frequency of low and high
cytokine-producers amongst indeterminate chagas
disease patients
Aiming to further apply the concept of Low and High
cytokine producers, we investigate the cytokine profile
after Bz-chemotherapy in patients with Indeterminate
Chagas disease (Figure 5A and B, bottom panels).
Data analysis further confirmed the broad cytokine
down-regulation in both innate and adaptive immunity
compartment after Bz-treatment (Figure 5A bottom
panel).
Upon in vitro antigen stimulation, the leucocytes from



























































Figure 3 Analysis of intracytoplasmic cytokine profile of CD8+. T-lymphocytes in the peripheral blood from untreated Indeterminate
chagasic patients (IND gray rectangle), Bz-treated Indeterminate chagasic patients (INDt black rectangle) as compared to non-infected individual
(NI empty rectangle). Data are expressed as median absolute counts plus the interquartile range of cytokine+ cells observed after short-term
in vitro “Control Culture” (top panel) and T. cruzi epimastigote antigen “Stimulated Culture” (bottom panel) of whole-blood samples. Cytokine+
CD8+ T-cells were quantified by dual color immunophenotyping (anti-CD8-TC plus anti-cytokine-PE mAbs) using specific gate strategy, as
described in Material and Methods. The significant differences at p< 0.05 for comparisons with NI are indicated by the letter ‘a’. The significant
differences at p< 0.05 for comparisons with INDt are indicated by connecting lines. The significant differences at p< 0.05 for comparative
analysis between “Control” and “Stimulated” cultures are indicated by *.
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profile toward a type 1 modulated pattern, characterized
by enhanced frequency of High cytokine producers in-
cluding IFN-γ from NK-cells and TNF-α and IFN-γ
from CD8+ T-cell along with IL-12 and IL-10 from
monocytes (Figure 5A and B, bottom panels).
Discussion
The first insight to use trypanocidal chemotherapeutic
drugs in patients with Chagas disease started almost
eighty years ago [19]. However, at the present, only Nfx
and Bz are clinically available worldwide for the etio-
logical treatment of Chagas disease, with the latter been
the main anti-parasitic drug used in Brazil. Despite the
effectiveness of Bz to parasite eradication during acute
phase of T. cruzi infection, the limited efficacy during
chronic Chagas disease, besides the high frequency of
undesirable side effects have contributed to refuse its
use to treat over 8 million patients with chronic Chagas
disease [5]. Previous reports have shown that, despite
the lack of parasite eradication, the etiological treatment
contribute to reduce the parasitemia and rearrange the
host immune response, leading to balanced inflamma-
tory response crucial to control Chagas disease morbid-
ity [7,9,13,14,20]. Regardless these insights, there are still
few studies focusing on the immunological changes fol-
lowing Bz-treatment during chronic Chagas disease
[13,14,21-23]. A coherent understanding of the immuno-
logical following Chagas disease etiological treatment
will certainly contribute to determine new perspectives
for immunoprevention, therapy, intervention and man-
agement [24,25]. In this context, it is important to
mention that the development of longitudinal studies
would be the choice to avoid possible experimental bias
due to particular features of the individual immune re-
sponse. However, longitudinal interventions presents be-
sides the difficulty to establish long-term follow-up of
patients, a large gap between the first and the second
evaluation, especially when focusing on long-lasting fea-
tures, that would introduce a relevant variable to the ex-
perimental approaches, mainly due to the reagent lots
and equipment performances.
In this study, we have performed a cross-sectional in-
vestigation to verify whether the Bz-therapy would in-
duce a long-lasting impact on the immunological status
of treated patients leading to a Type-1 modulated cyto-
kine profile likely that observed early after the end of the
treatment [13,14]. For this purpose, we have first charac-
terized the cytokine profile of circulating leucocytes
from untreated IND patients in order to establish a
baseline to evaluate the impact of etiological treatment
during chronic T. cruzi infection.
Our data showed that untreated IND patients pre-
sented in the ex vivo analysis (Control Culture) an over-
all type-1 regulated cytokine profile in the innate
immune compartment (IL-10 from neutrophils, IL-12
and IL-10 from monocytes and IFN-γ from NK-cells)
and a predominant type-2 profile in the adaptive im-
munity cells (IL-4 from CD4+ T-cells, IL-10 from CD8+
T-cells and B-lymphocytes). It was interesting to notice
that the cytokine profile of innate and adaptive immun-



















































Figure 4 Analysis of intracytoplasmic cytokine profile of B-cells in the peripheral blood from untreated. Indeterminate chagasic patients
(IND gray rectangle), Bz-treated Indeterminate chagasic patients (INDt black rectangle) as compared to non-infected individual (NI empty
rectangle). Data are expressed as median absolute counts plus the interquartile range of cytokine+ cells observed after short-term in vitro “Control
Culture” (left panel) and T. cruzi epimastigote antigen “Stimulated Culture” (right panel) of whole-blood samples. Cytokine+ B-cells were quantified
by dual color immunophenotyping (anti-CD19-TC plus anti-cytokine-PE mAbs) using specific gate strategy, as described in Material and Methods.
The significant differences at p< 0.05 for comparisons with NI are indicated by the letter ‘a’. The significant differences at p< 0.05 for
comparisons with INDt are indicated by connecting lines. The significant differences at p< 0.05 for comparative analysis between “Control” and
“Stimulated” cultures are indicated by *.
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These findings showed that untreated IND patients
are able to mount a pro-inflammatory cytokine response
supported by enhanced levels of IL-12+ monocytes and
IFN-γ+ NK-cells. However, this inflammatory response
seems to be regulated in Indeterminate clinical form, to
consequently prevent the disease progression, by the es-
tablishment of modulatory mechanisms that involve the
participation of IL-10 from neutrophils, monocytes, CD8+
T-cells and B-cells. Our findings showed an increased
frequency of inflammatory-like monocytes and NK-cells,
together with high levels of regulatory-like monocytes and
modulated adaptive immunity that could be important to
the establishment/maintenance of asymptomatic chronic
Chagas disease. Previous studies have shown that the estab-
lishment of an inflammatory immune response mediated
by monocytes and NK-cells are essential to control T. cruzi
infection [26,27] and that the ability to mount immunore-
gulatory mechanisms in both innate [28] and adaptive
immunity [19] are essential to control the inflammatory
immune activity and are apparently necessary to prevent a
deleterious effect of anti-T. cruzi immune response during
asymptomatic chronic Chagas disease.
The analysis of High and Low cytokine producers has
been proposed by Bahia-Oliveira et al. [17] and further
applied by Vitelli-Avelar et al. [18] to evaluate the cyto-
kine profile of Chagas disease patients. Using this ap-
proach, our data further confirmed the cytokine profile
described above. Additionally, our findings pointed out
the presence of increased frequency of High IL-10 pro-
ducers within CD4+ T-cells, but still lower than the fre-
quency of High IL-10 producers within monocytes.
These data re-inforce previous reports form Gomes
et al., [28] demonstrating that in IND the majority of the
IL-10-producing cells are monocytes. Moreover, our data
showed that enhanced frequency of High IFN-γ produ-
cers could be identified within CD8+ T-cells in IND, not
detectable by the conventional analysis. This finding is
also in agreement with those presented by Gomes et al.
[28] showing that around 60% of the IND could be iden-
tified as High IFN-γ producers. These authors suggested
that the IND patients that are high IFN-γ producers are
candidates to develop cardiomyopathy sooner than those
lower producers. On the other hand, it is possible that





































































































































































































































































































Figure 5 Frequency of low cytokine-producers (empty rectangle). High inflammatory cytokine-producers (black rectangle) and high
regulatory cytokine-producers (gray rectangle) for each leukocyte subset in the peripheral blood from untreated Indeterminate chagasic patients
(IND) and Bz-treated Indeterminate chagasic patients (INDt) using the median percentage of cytokine+ cells from the group of non-infected
individuals as the cut-off edge. Color diagrams (left panels) were first assembled for individual samples to further compile the resultant frequency
(right panels) of cytokine producers in the “Control Culture” (A) and T. cruzi epimastigote antigen “Stimulated Culture” (B) of whole-blood
samples. Statistical significance at p< 0.05 for comparisons between “Control” and “Stimulated” cultures are represented by *. (C) Representative
dot plots illustrating the overall cytokine down-regulation after Bz treatment, as well as the in vitro antigen stimulation shifted the cytokine profile
toward a type 1-modulated profile.
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IL-10 secretion has less chance to develop cardiac dis-
ease [28]. Human longitudinal studies under evaluation
by our group will be able to validate this hypothesis.
As IND is not necessarily a permanent clinical form,
with approximately 36% of them eventually developing
severe cardiac disease [1], any effort that could make to
maintain the IND clinical status, apart from parasito-
logical cure, would be relevant to control Chagas disease
morbidity. It has been suggested that the etiological
treatment could be employed to maintain the stable In-
determinate clinical form and prevent the disease pro-
gression, despite the parasitological cure [7-9,21]. Since
impairment in the cytokine network has been pointed
out as one of the determining factors driving disease
morbidity [2,18], it is possible that if the etiological treat-
ment would be able to introduce changes in the cytokine
network towards immunodulatory mechanisms, it could
contribute to prevent the disease progression. In this
study, we have characterized the cytokine profile of cir-
culating leucocytes from treated INDt patients, seven
years after the end of Bz chemotherapy and compared
with that observed in untreated IND patients.
Our data showed that treated INDt patients presented, in
the ex vivo analysis (Control Culture), an overall down-
regulated cytokine profile in both, innate immunity (IL-12
and IL-10 from neutrophils and monocytes besides IFN-γ
from NK-cells) and adaptive immune compartment (IL-12,
TNF-α, IFN-γ and IL-5 from CD4+ T-cells and IL-10 from
B-cells), along with basal levels of cytokine-expressing cells
within CD8+ T-lymphocytes. The overall down-regulation
in the cytokine synthesis observed seven years after the end
of Bz-treatment is in agreement with previous reports the
immunomodulatory effect of Bz in experimental models
[21,29,30]. This modulated profile may account for the gen-
eral hypothesis that the Bz-treatment during chronic
Chagas disease may has a supportive impact, modulating
the inflammatory cytokine profile of peripheral blood leu-
cocytes from IND reducing the chances of progression to
cardiac disease [13,14,21]. However, this down-regulation
in the cytokine profile may shortly favor the parasite repli-
cation from residual inflammatory foci, considering the low
effectiveness of Bz-treatment to promote parasite clearance
during chronic Chagas disease [31-33]. To investigate the
possible impact that residual T. cruzi antigens would have
on the immune response of Bz-treated INDt patients, we
have characterized the cytokine pattern triggered upon
in vitro T. cruzi antigen stimulation. Interestingly, our data
showed that the cytokine profile of innate and adaptive im-
munity cells was greatly impacted by the antigenic stimula-
tion. In fact, the in vitro antigen stimulation was able to
emerge the cytokine synthesis mainly in monocytes (IL-12
and IL-10), NK-cells (IFN-γ) and CD8+ T-cells (IFN-γ),
characterizing an overall type 1-modulated immune profile.
The analysis of High and Low cytokine producers further
confirmed the impact of T. cruzi antigens on the cytokine
pattern of INDt. This modulated pro-inflammatory cyto-
kine pattern resemble that observed in children treated dur-
ing early Indeterminate Chagas disease (E-INDt), by the
ability of NK-cells and CD8+ T-cells to produce IFN-γ [14].
However, there was a major difference regarding the source
of modulatory IL-10 in INDt (monocytes) and E-INDt
(CD4+ T-cells and B-lymphocytes) [14].
The ability of the immune system to generate stable
memory CD8+ T-cell after pathogen clearance during
acute and chronic infection have been already shown in
experimental T. cruzi infection [21,34]. These authors
have shown that Bz-induced cure drives conversion of the
immune response to a stable and protective CD8+ T-cell
central memory response, capable of showing effector func-
tion and providing protective immunity upon re-challenge
[21,34]. In agreement with our data, the Bz-treatment does
not result in the full retention of CD4+ T-cells able to recall
cytokine production upon antigenic stimulation [21]. It has
been shown that Bz-treatment of infected hosts leads to a
selective expansion of effector and memory CD8+ T-cells
able to protect the hosts against re-infection. These findings
allow these authors to hypothesize that besides the direct
role in blocking the parasite replication in vivo, Bz-
treatment appears to positively affect the antigen-driven
host immune system and thus maintain the participation of
immuneprotective effector mechanism in the anti-
pathogen response. Therefore, the effectiveness of any
chemotherapy protocols should consider not only the try-
panocidal effect but also its impact on the host immune
response.
Additional studies are still needed to better understand
the impact of Bz-treatment on the immune system of
patients at distinct clinical forms of Chagas disease. As
previously reported, we are currently investigating the
impact of Bz-treatment on the immunological status on
cardiac Chagas disease patients [14]. Preliminary data
have pointed out the beneficial impact of Bz-treatment
in the immunological profile in cardiac patients increas-
ing the frequency of IL-10+ monocytes, an important
immunomodulatory event to control deleterious anti-
parasite immune-mediated inflammatory mechanisms [18].
The ability of Bz to induce the persistence of antigen-
specific memory CD8+ T-cells in cardiac patients are cur-
rently under evaluation by our group.
Conclusion
In summary, our findings showed that the Bz treatment
of Indeterminate Chagas’ disease patients shifts the cyto-
kine patterns of peripheral blood monocytes, NK-cells and
CD8+ T-cells towards a long-lasting Type-1-modulated
profile that could be important to the maintenance of a
non-deleterious immunological microenvironment.
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